Guide for patients & caregivers
Atypical Ductal Hyperplasia (ADH) on Breast Biopsy: What Now?
Atypical ductal hyperplasia (ADH) on a breast biopsy explained: why excision is often discussed, what future risk means in plain terms, and follow-up screening.
Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles
What does atypical ductal hyperplasia on a breast biopsy mean?
Atypical ductal hyperplasia (ADH) on a breast biopsy means the cells lining one or more milk ducts have increased in number and developed an unusual shape or pattern. It is a benign (non-cancerous) finding. Because it can sit next to more significant changes and is linked with higher future risk, more tissue is often removed and follow-up is usually arranged.
This guide explains the report term and the usual next steps in general terms. It cannot say what your own tissue will show or what your personal risk is. Your breast team weighs the biopsy result together with your imaging, age, family history and other factors.
Breast changes to get checked sooner
Do not wait for a planned mammogram or clinic visit if you notice something new. Cancer Research UK advises contacting your doctor about any new breast change. NHS guidance lists these changes to get checked by a GP:
- A lump or swelling in the breast, chest or armpit.
- Dimpling or orange-peel skin, or a change in skin colour on the breast.
- A change in the size or shape of one or both breasts.
- Nipple discharge when not pregnant or breastfeeding, especially if bloody.
- A nipple that turns inwards, changes shape, or develops a rash.
Is ADH cancer or a precancer?
ADH is not cancer, and it is not stage 0 breast cancer. Cleveland Clinic explains that ADH cells share some features with ductal carcinoma in situ (DCIS), an early non-invasive cancer, which is why pathologists flag them. Cancer Research UK notes that atypical cells may stay the same, die off or return to normal; they do not necessarily become cancer.
ADH is different from atypical lobular hyperplasia (ALH), which affects the milk-producing lobules rather than the ducts. Usual ductal hyperplasia, without atypia, is a separate finding again; Breast Cancer Now says it needs no treatment or follow-up. Check which term is on your report.
In the UK, you may see your biopsy coded as B3, meaning a lesion of uncertain malignant potential. The 2024 Sloane study describes atypia, including ADH, as a B3 finding seen in about 5 to 10 in 100 needle biopsies in the English breast screening programme. A B3 code is not a cancer diagnosis; it signals that the team needs more information before deciding on next steps.
ADH rarely causes symptoms on its own. It is usually found by chance, often when tiny calcium specks on a screening mammogram are biopsied. If you felt a lump, Cancer Council Victoria notes that the lump itself is usually something else, such as fibrous tissue.
Why is surgical excision or vacuum excision discussed?
A needle biopsy takes only small samples. The main reason for removing more tissue is to make sure no DCIS or invasive cancer lies next to the area sampled. Cleveland Clinic reports that precancerous or cancerous cells are found in up to about 1 in 5 operations for ADH. Put the other way, most excisions find no cancer.
Breast Cancer Now and Cancer Research UK describe two ways to remove the area:
- Vacuum-assisted excision: under local anaesthetic, a needle attached to a vacuum device, guided by mammogram or ultrasound, removes the area through a small cut. This can avoid an operation under general anaesthetic.
- Surgical excision biopsy: a small operation under local or general anaesthetic, used when vacuum excision is not suitable. It leaves a scar that fades over time.
What does ADH mean for future breast cancer risk?
ADH raises the chance of breast cancer later, in either breast, but most people with ADH do not develop breast cancer. Cleveland Clinic states that atypical hyperplasia may make breast cancer up to four times more likely than for someone without it. It also quotes figures of about 7 in 100 people developing breast cancer after 5 years, about 13 in 100 after 10 years and about 30 in 100 after 25 years.
Newer UK data are more reassuring in the short term. A 2024 study of more than 3,000 women with atypia found through English breast screening found about 45 breast cancers per 1,000 women by six years. Women diagnosed more recently had lower short-term rates. The authors suggest some atypia picked up by modern mammography may be a risk marker rather than something that would cause harm soon.
These numbers are averages across groups. Your own risk also depends on age, family history and other factors, so ask your team to put it in context.
What follow-up and screening happen after ADH?
Follow-up varies between countries and hospitals. Breast Cancer Now says it is decided case by case, and may include yearly mammograms. Cancer Research UK mentions clinic visits and a mammogram every one to two years. Cancer Council Victoria describes annual mammograms and breast examinations, and yearly rather than two-yearly screening for women staying in BreastScreen Australia.
Cleveland Clinic adds that some people may qualify for breast MRI, and that people at higher overall risk may discuss risk-reducing medicines that block oestrogen, such as tamoxifen, with their doctor. Whether any of these suit you depends on your full risk picture and is a decision to make with your team.
Being breast aware still matters between scans. Report changes promptly rather than waiting for the next appointment.
Questions to ask your breast team
Bring the pathology report and imaging results, and note the answers beside each question.
- Does my report say atypical ductal hyperplasia, atypical lobular hyperplasia or something else?
- Do the biopsy findings match what the imaging showed?
- Do you recommend removing more tissue, and would that be vacuum excision or surgery?
- What did the excision show, and does it change my plan?
- How does ADH change my own risk, given my age and family history?
- What screening will I have, how often and for how long?
- Should I discuss risk-reducing medicines, MRI or a referral to a family history clinic?
How comparing similar cases on SameCase can help
On SameCase, patients and verified doctors share de-identified cases. Seeing how others with an ADH result discussed excision choices or screening plans can help you frame your own questions. Every case differs, so other people's experiences cannot diagnose you or predict your outcome. Take any questions they raise to your breast team.
Sources and further reading
- Breast Cancer Now: Hyperplasia and atypical hyperplasia leaflet (BCC78, October 2024)
- Cancer Research UK: Atypical hyperplasia in a breast lump
- Cleveland Clinic: Atypical ductal hyperplasia (updated November 2023)
- Cancer Council Victoria: Atypical ductal hyperplasia
- Freeman K, et al. Atypia detected during breast screening: Sloane cohort, BMJ 2024 (CC BY, PMC)
- NHS: Symptoms of breast cancer in women (reviewed March 2024)
For patients & caregivers
Share your case and learn from others
Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.